Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock experienced volatility over the past six months. A bull run occurred in late October following news of full enrollment in the Phase 3 study for lonvo-z in hereditary angioedema. However, the stock tumbled after a patient death led to an FDA clinical hold on the MAGNITUDE-2 study. The stock price recovered in late January 2026 after the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z.

Intellia Therapeutics' products and services do not exhibit typical demand seasonality. Demand for its investigational therapies is driven by the prevalence and incidence of specific medical conditions and the progression of its clinical pipeline. Demand is influenced by clinical trial results, regulatory milestones, and market access, rather than seasonal fluctuations.

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing curative genome editing therapies using CRISPR/Cas9. The company's lead in vivo programs include Nexiguran Ziclumeran for transthyretin amyloidosis and Lonvoguran Ziclumeran for hereditary angioedema, both in late-stage clinical trials. Intellia is also engaged in research programs for Hemophilia B, immuno-oncology, autoimmune diseases, alpha-1 antitrypsin deficiency, and other genetic disorders.

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, and primarily operates and conducts clinical trials within the United States, with therapies aimed at addressing global unmet medical needs.

Intellia Therapeutics' brand reputation has been influenced by clinical trial progress and safety outcomes. The company is viewed as a pioneer in genome editing. Analyst sentiment is mixed, with a consensus rating of "Hold". Key events affecting its reputation include positive clinical trial progress, the clinical hold and patient death in the MAGNITUDE-2 study, and the subsequent FDA clinical hold lift. Valuation metrics indicate its speculative nature as a biotechnology company.

Intellia Therapeutics' stock is owned by a mix of institutional investors (46.11%), insiders (1.82%), and public companies and individual investors (52.07%). Major institutional owners include The Vanguard Group, ARK Investment Management LLC, and BlackRock, Inc. Caribou Therapeutics Holdco LLC is the largest individual shareholder. Recent insider trading activity shows a net insider selling of $905,980, with a significant buy transaction of $1.4 million by Fred E. Cohen.